Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

NCT01121705 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

360

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis

Interventions

DRUG: Peg Interferon alpha2b + Ribavirin

Sponsor

Casa Sollievo della Sofferenza IRCCS